Search Results 231-240 of 16754 for GLP-1 agonists
... 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a ... Treatment with GLP-1 RAs within 90 days prior to Vl. Presence of acute ...
Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence after Liver Transplantation ... 1 trial. Phase 4 trials ...
The best one for you depends on many things, including your overall health. For example, an ACE inhibitor may help if you have chronic kidney disease ...
Other genes can increase the risk of getting certain diseases, including AATD. One gene tells the liver to make alpha-1-antitrypsin (AAT or A1AT) protein. This ...
This medicine is given through an IV catheter that is placed in one of your veins. ... You may report side effects to the FDA at 1-800-FDA-1088. Back to top. Drug ...
The goal of this study is to understand how and why insulin resistant individuals respond differently to exercise as compared with insulin sensitive individuals ...
Safety and efficacy have not been established in children younger than 1 month of age with chronic kidney disease who are on dialysis, in children younger than ...
About this study. This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called ...
If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Abemaciclib; Abiraterone Acetate ...
If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Bromperidol; Kava; Kratom ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.